JNJ - earlier PR: Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo Car-T Programs and Transform Autoimmun
JNJ - earlier PR: Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo Car-T Programs and Transform Autoimmune Disease Through Immune Reset -Johnson & Johnson Partners With Sail Biomedicines On In Vivo Car-T Therapies, Secures $2.58B Acquisition Option; To Invest $785M In Sail, Expects The Agreements To Dilute Adjusted Operational Earnings Per Share And Adjusted Earnings Per Share By ~$0.18 In 2026 And ~$1.28 In 2027
JNJ - earlier PR: Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo Car-T Programs and Transform Autoimmune Disease Through Immune Reset -Johnson & Johnson Partners With Sail Biomedicines On In Vivo Car-T Therapies, Secures $2.58B Acquisition Option; To Invest $785M In Sail, Expects The Agreements To Dilute Adjusted Operational Earnings Per Share And Adjusted Earnings Per Share By ~$0.18 In 2026 And ~$1.28 In 2027